Powered by Blogger.

HIV treatment information

google.com, pub-5877111316406693, DIRECT, f08c47fec0942fa0
Reputation of the HIV virus which has been difficult to tame it seems to be coming to an end. The results of two studies conducted in Africa to mention a pill called Truvada can prevent AIDS virus infection in men and heterosexual women.


Beginning in 2011 a study says Truvada pill can not prevent transmission of the AIDS virus. But two recent studies funded by the U.S. disease control center (CDC) said the pill successfully prevent AIDS.

The study was conducted in Botswana, Africa, involving 1,200 men and women. Half of the respondents are given a pill taken daily Truvada. The rest get a placebo pill or a pill with no active substance as a comparison.

The results of the analysis found the respondent of the Truvada group believes they will not be infected with HIV. However, there are 4 people from this group are infected. Meanwhile the control group was found 19 people infected with HIV. This means Truvada reduce the risk of HIV infection by 78 percent.

A second study funded by the Bil & Melinda Gates Foundation and conducted by a team from the University of Washington heteroksesual involving 4700 couples in Kenya and Uganda. From each pair, one of whom is infected with HIV. Then uninfected given a pill Truvada or other HIV prevention pill, Viread. The rest got a placebo pill.

The result there are 13 people infected with HIV from the group Truvada, Viread group and 18 of 47 people from the placebo pill group. In other words, giving the pill reduces the risk of HIV by 62 percent to 73 percent.

Besides giving a pill, in both studies respondents were also given counseling and free condoms so it is quite reasonable if low levels of infectivity.

This latest study is the fourth largest studies in the search for AIDS drugs. The first study conducted in homosexual men in Peru, Ecuador, Brazil, South Africa, Thailand, and the United States. Truvada drugs are administered is known to decrease the risk of infection by 44 percent and 73 percent in men who discipline taking this medication.

Although welcomed, but Gilead Sciences, Truvada manufacturers have not planned to make the drug in bulk. Scientists are still investigating why the study on 3900 women in Kenya, Tanzania, and South Africa, this pill does not give encouraging results.

Drugs Truvada and Viread in these studies produced by Gilead Sciences, the major pharmaceutical companies that produce AIDS drugs. This week U.S. health officials announced the company has agreed to produce a generic drug is to be accessed by residents of poor countries.

0 comments:

Post a Comment